GlassScriptPhysician profile
Antonette O Whitehead
NPI 1073707071
$2,178.61
in general payments reported to CMS, 2019-2025
21 companies · $636 in 2025
The $636 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $47.52 · 2021: $168 · 2022: $264 · 2023: $157 · 2024: $493 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $387.09 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $343.30 | 2022-2025 | |
| Exeltis, USA INC. | $331.67 | 2019-2024 | Slynd |
| Organon LLC | $196.53 | 2021-2025 | Nexplanon |
| Avion Pharmaceuticals | $146.47 | 2019-2021 | |
| Coopersurgical, INC. | $136.54 | 2022-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $94.96 | 2019-2025 | Gardasil 9, Gardasil |
| Biogen, INC. | $88.43 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $69.84 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $52.05 | 2024 | Myfembree |
| Millicent US INC | $45.19 | 2019-2025 | Intrarosa |
| Allergan, INC. | $43.61 | 2019 | |
| Therapeuticsmd, INC. | $42.16 | 2019 | |
| Vertical Pharmaceuticals, LLC | $39.90 | 2019 | |
| Myovant Sciences INC. | $38.26 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $34.47 | 2019 | |
| Solventum Corporation | $34.45 | 2025 | Prevena, 3m Cavilon, Activ.A.C. |
| Amag Pharmaceuticals, INC. | $19.66 | 2019 | |
| Hologic Sales and Service, LLC | $17.06 | 2025 | Aptima |
| Agile Therapeutics, INC. | $16.97 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonette Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.